Objectives: Dibromomannitol (DBM) has been used, in conditioning regimens for BMT since 1982 in Hungary. Population pharmacokinetic analysis of the drug was carried out in 30 patients undergoing bone marrow transplantation, as well as in 24 patients after single oral dose of 500 mg (test dose) pre-transplant. The pharmacokinetic data of the single oral dose was compared with the pharmacokinetic and pharmacodynamic results of the repeated doses in the conditioning regimen. Methods: DBM was assayed in plasma using the previously described HPLC method (13). Results: A significant proportion of the variability of pharmacokinetic parameters could be attributed to sex, and also to age in women. The occurrence of acut GVHD was highly correlated with the increased AUC. ft has been demonstrated that peak concentrations lower than 25 μM in male patients receiving test dose predispose to relapse. Conclusions: Therapeutic monitoring should produce improved results in patients undergoing BMT by both decreasing treatment-related toxicity and improving antitumor activity.
|Number of pages||6|
|Publication status||Published - dec. 1 1999|
ASJC Scopus subject areas